Experience with the natural non-hormonal drug Serelis in the therapy of menopausal syndrome in surgical menopausal women
- Authors: Gavrilov M.V.1, Puchkina G.A.2, Ermolenko N.S.1, Simacheva S.A.2, Sulima A.N.2
-
Affiliations:
- JSC "Meditsina" (Medicine) (Academician Roitberg Clinic)
- S.I. Georgievsky Medical Academy V.I. Vernadsky Crimean Federal University
- Issue: No 9 (2021)
- Pages: 134-144
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249426
- DOI: https://doi.org/10.18565/aig.2021.9.134-144
- ID: 249426
Cite item
Open Access
Access granted
Abstract
Objective: To estimate changes in the frequency and severity of menopausal syndrome (MS) symptoms and psychoemotional disorders and the frequency of adverse events 12 weeks after the end of taking the natural non-hormonal drug (NHD) Serelis. Materials and methods: The investigation enrolled 90 surgical menopausal patients with MS (45 in the Serelis group and 45 in the placebo group). The investigation lasted 36 weeks. Changes were estimated in the frequency and severity of MS symptoms, in particular psychoemotional disorders, quality of life, and the frequency of adverse events. Results: After 12 weeks of treatment, there was a decrease in the severity of MS in 40/45 (88.9%) patients in the Serelis group versus 9/45(20%) in the placebo group (OR 1.12; 95% CI 0.90-4.02, p=0.048). The Serelis group showed a statistically significant decrease in the severity of neurosplanchnic and psychoemotional symptoms on the MMI scale (p=0.018 and p=0.017, respectively), the changes in the placebo group were statistically insignificant. The median total MMI score was 33.2 in the Serelis group (p=0.034) and 50.1 in the placebo group (p=0.046). There were no statistically significant differences in the total HADS scores between the groups (p=0.048). According to the WHQ questionnaire, the decrease in the mean total score amounted to as much as 33.3% in the Serelis group and 5.3% in the placebo group (p<0.001). Serelis use in the follow-up period had a long-lasting positive impact. Conclusion: The results of our study have shown that the use of the NHD Serelis allows one to achieve a signif icant reduction in the severity of neurosplanchnic and psychoemotional symptoms, to level off anxiety-depressive spectrum disorders, and to significantly improve quality of life.
Full Text
About the authors
Mikhail V. Gavrilov
JSC "Meditsina" (Medicine) (Academician Roitberg Clinic)
Email: centr.gyn@yandex.ru
Head of the Center of Gynecology and IVF Clinic of Academician Roitberg 125047, Russia, Moscow, 2nd Tverskaya-Yamskaya Lane, 10
Galina A. Puchkina
S.I. Georgievsky Medical Academy V.I. Vernadsky Crimean Federal University
Email: puchkina.g.a@mailru
Assistant of the Department of Obstetrics, Gynecology and Perinatology No. 1 295051, Russia, Republic of Crimea, Simferopol, Lenin str., 5/7
Nianila S. Ermolenko
JSC "Meditsina" (Medicine) (Academician Roitberg Clinic)
Email: ermolenko.n@medicina.ru
obstetrician-gynecologist of the hospital 125047, Russia, Moscow, 2nd Tverskaya-Yamskaya Lane, 10
Svetlana A. Simacheva
S.I. Georgievsky Medical Academy V.I. Vernadsky Crimean Federal University
Email: simacheva_svetla@mail.ru
Associate Professor of the Department of Obstetrics, Gynecology and Perinatology No. 1 295051, Russia, Republic of Crimea, Simferopol, Lenin str., 5/7
Anna N. Sulima
S.I. Georgievsky Medical Academy V.I. Vernadsky Crimean Federal UniversityDr. Med. Sci., Professor of the Department of Obstetrics, Gynecology and Perinatology No. l 295051, Russia, Republic of Crimea, Simferopol, Lenin str., 5/7
References
- Овсянникова Т.В., Леваков С.А., Куликов И.А. Монотерапия эстрогенами у женщин с хирургической менопаузой. Гинекология. 2014; 16(6): 22-4. [
- Сметник В.Л. Климактерические расстройства и методы их коррекции. Cons. Med. Ucraine. 2008; 2 (12): 32-8.
- Бондаренко К.Р., Доброхотова Ю.Э., Насырова Н.И., Шадрова П.А. Терапия эстрогенами: от науки к практическим решениям. Акушерство и гинекология. 2020; 12: 67-75. https://dx.doi.org/10.18565/aig.2020.12.67-75.
- Кулавский В.А., Кулавский Е.В., Зиганшин А.М. Хирургическая менопауза у женщин репродуктивного возраста. Акушерство, гинекология и репродукция. 2016; 10(4): 105-13. https://dx.doi.org/10.17749/2313-7347.2016.10.4.105-113.
- Древаль А.В. Менопауза. РМЖ. 2018; 26(1-1): 3-7.
- Genazzani A., Panay N., Simoncini T., Depypere H., Mueck A. et al. Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. Gynecol Endocrinol. 2020 Mar; 36(3): 190-6. https://dx.doi.org/10.1080/09513590.2020.1722994.
- Appel K., Veit J., Diaz P., Palacios S. Purified and specific cytoplasmic pollen extract, PureCyTonin®, a non-hormonal treatment for hot flushes, inhibits serotonin reuptake. Gynecol Reprod Endocrinol Metabol. 2020; 1(1): 64-8.
- Elia D., Mares P. Evaluation de la tolerance et de l’efficacite d’un complement alimentaire Serelys® (Femal®) chez les femmes en periode de menopause. Genesis. 2008; 135: 12-5.
- Fait T., Sailer M., Regidor P.A. Prospective observational study to evaluate the efficacy and safety of the pollen extract Serelys® in the management of women with menopausal symptoms. Gynecol Endocrinol. 2019; 35(4): 1-4. https://dx.doi.org/10.1080/09513590.2018.1538347
- Lareva N.V., Govorin A.V. Psychosomatic relationships in postmenopausal women. Ter Arkh. 2013; 85(3): 86-9.
- Winther K., Rein E., Hedman C. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climateric. 2005; 8(2): 162-70. https://dx.doi.org/10.1080/13697130500117987.
- Goldstein S.R., Espie M., Druckmann R. Does purified Swedish pollen extract, a nonhormonal treatment for vasomotor symptoms, inhibit the CYP2D6 enzyme system? Menopause. 2015; 22(11): 1212-4. https://dx.doi.org/10.1097/GME.0000000000000535.
- Hellstrom A.C., Muntzing J. The pollen extract femal - a non-estrogenic alternative to hormone therapy in women with menopausal symptoms. Menopause. 2012;19(7):825-9. https://dx.doi.org/10.1097/gme.0b013e31824017bc.
- Druckmann R., Lachowsky M., Elia D. Evaluation de la qualite de vie, de l’efficacite et de la tolerance de Serelys chez les femmes en periode de peri-menopause et menopause. Genesis. 2015; 183: 10-3.
- Вихляева Е.М., ред. Руководство по эндокринной гинекологии. М.: Мед. информ. агентство; 1998. 765 с. 16. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983; 67(6): 361-70. https://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x.
- Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983; 67(6): 361-70. https://dx.doi.org/10.1111/j.1600-0447.1983.tb09716.x.
- Брюхина Е.В., Ивнова О.В., Усольцева Е.Н. Психометрические свойства русскоязычной версии опросника женского здоровья Womens Health Questionnaire (WHQ). Вестник ЮУрГУ. 2012; 42: 134-42.
- Giannini A., Caretto M., Genazzani A. et al. Optimizing quality of life through sex steroids by their effects on neurotransmitters. Climacteric. 2019; 22(1): 55-9. https://dx.doi.org/10.1080/13697137.2018.1543265.
- Rossmanith W.G., Ruebberdt W. What causes hot flushes? The neuroendocrine origin of vasomotor symptoms in the menopause. Gynecol Endocrinol. 2009; 25(5): 303-14. https://dx.doi.org/10.1080/09513590802632514.
- Svensson U. Report EUDAKG Eurofins Steins Laboratorium. Method EU 152/2009. AR-16-LW-035803-012016; 2009
- Стариков П., Федоров В. Использование Селанка в лечении вегетативных и психоэмоциональных расстройств при климактерическом синдроме у женщин. Врач. 2019; 30(12): 48-53.
Supplementary files
